Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia

Author： Wiernik Peter H.   Adiga Giridhar U.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.10, 2011-10, pp. : 1987-1993

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3805-3811

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Resistant/Relapsing Chronic Lymphocytic Leukemia with a Combination Regimen Containing Deoxycoformycin and Rituximab

By  

Acta Haematologica, Vol. 111, Iss. 4, 2004-05 ,pp. : 185-188

Karger

Access to resources Recommend Favorite

Ofatumumab for the treatment of chronic lymphocytic leukemia

By Robak Tadeusz  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 577-587

Future Medicine

Access to resources Recommend Favorite

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 511-514

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-05 ,pp. : 240-243

Karger

Access to resources Recommend Favorite